|
See related Cytarabine DBL inj[賽達命 注射劑] information |
|
|
|
製造商 |
Hospira |
|
代理/經銷商 |
HsinYi |
|
成份 |
Cytarabine |
|
適應症 |
Treatment of acute leukaemia, especially acute non-lymphoblastic leukemia. Blast crisis of chronic myeloid leukaemia, & in the treatment of lymphoma. |
|
用量 |
Acute non-lymphocytic leukemia 100 mg/m2/day (day 1-7) continuous IV infusion or every 12 hr. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
注意事項 |
Pregnancy. Impaired liver function. In addition to blood counts, blood-uric acid should be monitored. Renal & hepatic function should be periodically assessed. |
|
不良反應 |
Bone marrow depression, myelosuppression, granulocytopenia. Nausea & vomiting. Hepatic & renal dysfunction, neurotoxicity (particularly via the intrathecal route), rashes, oral & anal ulceration, GI haemorrhage, oesophagitis, & conjunctivitis. Syndrome of bone & muscle pain, fever, malaise, conjunctivitis & rash (described as flu-like). Anaphylactoid reactions. Local pain, cellulites & thrombophlebitis at the site of inj.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Inhibits the action of flucytosine. Antineoplastics.
View more drug interactions with Cytarabine DBL[賽達命] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Cytarabine DBL 注射劑 |
|
Cytarabine DBL 100 mg/1 mL x 5 mL |
|
|
|
Manufacturer: |
Hospira |
|
Distributor: |
HsinYi |
|
|
|
|
